A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Consequently, Cabometyx is now the first and only systemic treatment that is FDA-approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin ...

"It was encouraging to see that cabozantinib resulted in significant delays in disease progression in the CABINET trial—regardless of primary tumor site and grade ... a phase 3 pivotal trial ...

FDA approves Exelixis' Cabometyx for advanced neuroendocrine tumors before the April 3 action date ... depending on tumor grade and different requirements for prior therapy.

Median PFS among 99 patients with pNET who were randomized 2:1 to receive cabozantinib or placebo was 13.8 months vs 3.3 months ... regardless of primary tumor site and grade.

This marks the drug as the first systemic treatment approved by the FDA for previously treated NET regardless of the primary tumor ... grade, and other factors. The approval is based on the phase ...